Paving the way for positive
therapeutic outcomes

Professor of Biology & Biological Engineering and Koch Institute for Integrative Cancer Research, MIT

HAN is a co-lead PI of SMART CAMP and co-captain of Flagship 1.

BIRNBAUM Michael is a co-lead PI of SMART CAMP. He is also the Immune Cell Cross-cut (Cross-cut B) captain.

‍

YU is CAMP's Founding Co-Lead PI. He is also a founding PI of the Mechanobiology Institute @ NUS, and the A*STAR Institute of Bioengineering and Nanotechnology.

Identification of immunological related critical quality attributes (CQA) for manufacturing CAR-T cells.

Adventitious viruses and associated safety CQAs.

Automation of cell culturing/measurement systems through software-hardware integration & instrumentation of components.

Averil is CAMP’s Lab Manager. With several years of experience and expertise in the biomedical field, she currently manages the operations, safety, events management and administration for CAMP lab.

‍

‍

Magnetic Resonance Relaxometry and Raman spectroscopy as label free tools for assessing quality and safety of iPS and spinal cord progenitor cells in cell therapy and manufacturing

‍

Computational modelling of dynamic biological processes

Developing a manufacturing pipeline for the expansion of clinical grade iPSCs

MSC critical quality attributes (CQA) and in-vivo validation

Investigating label-free biophysical and biochemical CQAs for CAR-T immune therapy using precision single cell microfluidic technologies.

Developing nanopore sensors for fingerprinting microbial contaminants.

Development of micro/nano technologies for biomedical and clinical applications.

Adventitious viruses and associated safety CQAs.

Immune cell therapy characterization.

Handling bacterial cultures and various extraction processes for sequencing and analysis.

Development of predictive models to complement investigation of label-free biophysical CQAs for immunotherapy.

Developing miniature fluidic instrumentation for sterile fluid extraction from cell culture vessels for optical measurements.

MSC characterizatation from patients and donors.

Testing of new CRISPR/Cas based diagnostic methods for adventitious agent detection.

Immune cell therapy characterization, CQAs, and PATs.

Next generation sequencing pipeline development for the identification of adventitious agents in cell therapy cultures.

Investigating predictive biophysical markers for efficacious clinical CAR-T products and multimodal label-free sorting/profiling of MSCs.

Identification of critical quality attributes (CQA) and development of in process control with CQA outputs for MSC cell therapy manufacturing.

Manufacturing of CAR-T cells.

Development of new CRISPR/Cas based diagnostic methods and CRISPR/Cas-based adventitious agent detection.

Developmentof bacterial culture for extraction process, PCR and DNA sequencing analysis

Investigate extracellular vesicles related critical quality attributes (CQA) for MSC therapy manufacturing.

MSCs and microcarriers fabrication for tissues regeneration.

Bala Narayanan is CAMP's Senior Program Manager. He brings years of experience in R&D program management and process engineering in industry and academic research settings.

Lee is CAMP's Scientific Director. Dr. Lee brings experience from working with the various stakeholders in biomedical research and technology and translation to positive outcomes for patients.

Electrical Engineering and Computer Science

‍

MIT Center for Biomedical Innovation

Health Sciences & Technology Program of Harvard and MIT

Mechanical Engineering

Biological Engineering

Research Laboratory of Electronics

Biological Engineering

Chemical Engineering

Mechanical Engineering

Electrical Engineering & Computer Science

MIT Koch Institute for Integrative Cancer Research

Research Laboratory of Electronics

Bioengineering

Mechanical Engineering

IGP HealthTech